The Daily Fuckup

The federal marijuana rewrite has split into two tracks, and the date that matters most for the hearing is June 29, not the start of the policy shift itself. On April 23, the Justice Department and DEA issued an order placing FDA-approved products containing marijuana and marijuana products covered by qualifying state medical licenses in Schedule III. That same action also set up an expedited administrative hearing on the broader proposal to move marijuana from Schedule I to Schedule III, with the hearing scheduled to begin June 29, 2026.

That distinction is the whole story. The April order took immediate effect for the covered products. The June hearing does not finish the job, and it does not sweep all marijuana into Schedule III. It starts a formal rulemaking process that can still run through objections, testimony, and more legal wrangling before the government reaches a final answer on the broader rescheduling proposal.

The practical stakes are obvious even if the paperwork is not. Federal scheduling still shapes research access, compliance burdens, and the way agencies treat cannabis-linked products. Moving some medical products into Schedule III does not legalize marijuana across the board, and it does not erase the conflict between federal law and state-legal markets. It does, however, mark a real federal change for a narrow set of products and a real procedural step toward a wider decision that has been delayed, debated, and relitigated for years.

For the industry, patients, researchers, and state regulators, the mixed message is familiar: one part of Washington has already changed the label, while another part is still arguing over the rest of the file. The result is not closure. It is a new hearing calendar, a narrower federal classification for some medical products, and another round of waiting for the bigger marijuana question to be answered.